Ogen 1.25 Pregnancy Warnings
There appears to be little or no increased risk of birth defects in children born to women who have used estrogens from oral contraceptives inadvertently during early pregnancy. There are no controlled data in human pregnancy.
AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.
US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Contraindicated
AU TGA pregnancy category: B1
US FDA pregnancy category: X
Comments:
-If pregnancy occurs, discontinue treatment immediately; there is no indication for use during pregnancy.
See references